GlassScriptPhysician profile
Taylor Aunon
NPI 1134812506
$2,239.70
in general payments reported to CMS, 2019-2025
20 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $135 · 2024: $1,024 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $485.62 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $368.65 | 2023-2025 | |
| Amgen INC. | $294.50 | 2024-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $202.28 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $163.34 | 2023-2025 | |
| Pfizer INC. | $139.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $104.46 | 2023-2025 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $82.63 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.84 | 2023-2025 | Synjardy, Jardiance |
| Exact Sciences Corporation | $62.94 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $56.74 | 2024-2025 | Freestyle Libre 3 |
| Irhythm Technologies, INC. | $42.02 | 2024 | Zio Monitor, Zio Xt Patch |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.80 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $30.74 | 2024 | Trelegy Ellipta |
| Cranial Technologies, INC | $19.69 | 2025 | Doc Band |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.48 | 2025 | Capvaxive |
| Medtronic, INC. | $17.97 | 2024 | Venaseal |
| Currax Pharmaceuticals LLC | $15.96 | 2024 | Contrave, Onzetra Xsail |
| Vanda Pharmaceuticals INC. | $14.73 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $14.31 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Aunon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.